Search

Displaying results 6491 - 6500 of 7056 in total
  1. Drug

    SLx-4090

    go.drugbank.com/drugs/DB05678
    Investigational

    SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]

  2. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    and a truncated portion of Pseudomonas exotoxin A. … VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.

  3. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  4. Drug

    Daxdilimab

    go.drugbank.com/drugs/DB16391
    Investigational

    Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).

  5. Drug

    Arundic acid

    go.drugbank.com/drugs/DB05343
    Investigational

    Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).

  6. Drug

    Bezisterim

    go.drugbank.com/drugs/DB05212
    Investigational

  7. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  8. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  9. Drug

    Biricodar

    go.drugbank.com/drugs/DB04851
    Investigational

    The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

  10. Drug

    Efprezimod alfa

    go.drugbank.com/drugs/DB16448
    Investigational

    CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.